Predicting the clinical outcome of melanoma using an immune-related gene pairs signature
Fig 4
Survival analyses after grouping according to gene mutation status in the TCGA-SKCM dataset.
(A) BRAF-mutated patients. (B) BRAF-wild-type patients. (C) NRAS-mutated patients. (D) NRAS-wild-type patients. All groupings, according to the genotypes, had no effect on the predictive validity of the markers.